Recombinant factor VIIa (rFVIIa, Novoseven®, Novo
Nordisk®, Denmark) is established for the management
of bleeding episodes in haemophiliac patients with inhibitors.
Interest has been growing in the use of this drug
for the management of severe intractable bleeding following
major trauma and surgery.
The potential role for recombinant factor VIIa in cardiac surgery
November 2004Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 77–AIC 79 Leave a commentClick any image to enlarge